Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 55, No 4 (2021)
Research Paper
Submitted: 2021-02-08
Accepted: 2021-03-09
Published online: 2021-06-16
View PDF Download PDF file
Get Citation

Migraine diagnosis and treatment in Poland: survey of primary care practitioners

Izabela Domitrz1, Aurelia Lipa2, Jacek Rożniecki3, Adam Stępień4, Wojciech Kozubski5
DOI: 10.5603/PJNNS.a2021.0045
·
Pubmed: 34132385
·
Neurol Neurochir Pol 2021;55(4):380-386.
Affiliations
  1. Department of Neurology, Faculty of Medical Sciences, Medical University of Warsaw, Warsaw, Poland, Cegłowska 80, 01-809 Warsaw, Poland
  2. Medical Department, Teva Pharmaceuticals Polska Sp. z o.o.,, Emilii Plater 53,, 00-113 Warsaw, Poland
  3. Department of Neurology, Stroke, and Neurorehabilitation, Medical University of Lodz,, Kopcińskiego 22, 90-153 Lodz, Poland
  4. Department of Neurology, Military Institute of Medicine in Warsaw, Szaserów 128, 04-141 Warsaw, Poland
  5. Department of Neurology, Charles Marcinkowski University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland

open access

Vol 55, No 4 (2021)
Research papers
Submitted: 2021-02-08
Accepted: 2021-03-09
Published online: 2021-06-16

Abstract

Aim of the study: This study aimed to analyze the daily clinical practice of primary care practitioners (PCPs) in Poland concerning migraine patients.

Clinical rationale for the study: Migraine is a common chronic primary headache disease, which can be disabling if insufficiently managed. Numerous studies suggest that migraine remains underdiagnosed and undertreated. The first consultation of migraine patients is usually undertaken by a PCP.

Materials and methods: This study was conducted in June and July 2019 in Poland using a computer-assisted web interview with 51 PCPs. The interview questions concerned knowledge of diagnostic criteria and methods of migraine treatment.

Results: On average, each PCP consulted 12 patients with migraine per month. More than half of PCPs (63%) listed partial diagnostic criteria for migraine without aura or mentioned aura in their responses. Only 10% of PCPs listed all diagnostic criteria for migraine without aura. Although 55% of PCPs said that they distinguished between episodic and chronic migraine, 18% provided the wrong definition. The most commonly prescribed drugs were triptans (66%), paracetamol, metamizole, or non-steroidal anti-inflammatory drugs (42%).

Conclusions and clinical implications: PCPs play a critical role in diagnosing, treating, and monitoring migraine; however, many of them have insufficient knowledge about its diagnosis and correct differentiation between chronic and episodic forms.

Abstract

Aim of the study: This study aimed to analyze the daily clinical practice of primary care practitioners (PCPs) in Poland concerning migraine patients.

Clinical rationale for the study: Migraine is a common chronic primary headache disease, which can be disabling if insufficiently managed. Numerous studies suggest that migraine remains underdiagnosed and undertreated. The first consultation of migraine patients is usually undertaken by a PCP.

Materials and methods: This study was conducted in June and July 2019 in Poland using a computer-assisted web interview with 51 PCPs. The interview questions concerned knowledge of diagnostic criteria and methods of migraine treatment.

Results: On average, each PCP consulted 12 patients with migraine per month. More than half of PCPs (63%) listed partial diagnostic criteria for migraine without aura or mentioned aura in their responses. Only 10% of PCPs listed all diagnostic criteria for migraine without aura. Although 55% of PCPs said that they distinguished between episodic and chronic migraine, 18% provided the wrong definition. The most commonly prescribed drugs were triptans (66%), paracetamol, metamizole, or non-steroidal anti-inflammatory drugs (42%).

Conclusions and clinical implications: PCPs play a critical role in diagnosing, treating, and monitoring migraine; however, many of them have insufficient knowledge about its diagnosis and correct differentiation between chronic and episodic forms.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

chronic migraine, episodic migraine, headache, primary care practitioner

About this article
Title

Migraine diagnosis and treatment in Poland: survey of primary care practitioners

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 55, No 4 (2021)

Article type

Research Paper

Pages

380-386

Published online

2021-06-16

Page views

1263

Article views/downloads

1063

DOI

10.5603/PJNNS.a2021.0045

Pubmed

34132385

Bibliographic record

Neurol Neurochir Pol 2021;55(4):380-386.

Keywords

chronic migraine
episodic migraine
headache
primary care practitioner

Authors

Izabela Domitrz
Aurelia Lipa
Jacek Rożniecki
Adam Stępień
Wojciech Kozubski

References (31)
  1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002; 346(4): 257–270.
    CrossRefPubMed
  2. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010; 30(5): 599–609.
    CrossRefPubMed
  3. Karbowniczek A, Domitrz I. Frequency and clinical characteristics of chronic daily headache in an outpatient clinic setting. Neurologia i Neurochirurgia Polska. 2011; 45(1): 11–17.
    CrossRef
  4. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain. 2005; 6(6): 429–440.
    CrossRefPubMed
  5. Linde M, Dahlöf C. Attitudes and burden of disease among self-considered migraineurs--a nation-wide population-based survey in Sweden. Cephalalgia. 2004; 24(6): 455–465.
    CrossRefPubMed
  6. Radtke A, Neuhauser H. Low rate of self-awareness and medical recognition of migraine in Germany. Cephalalgia. 2012; 32(14): 1023–1030.
    CrossRefPubMed
  7. World Health Organization, Lifting The Burden Atlas of headache disorders and resources in the world 2011. Geneva. 2011.
  8. Domitrz I, Lipa A, Rożniecki J, et al. Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies. Neurol Neurochir Pol. 2020; 54(4): 337–343.
    CrossRefPubMed
  9. Domitrz I, Lipa A, Rozniecki J, et al. Polish omnibus online survey on migraine conducted in a population of 2000 adults. Migrena news . 2019; 3(6): 98–100.
  10. Latinovic R, Gulliford M, Ridsdale L. Headache and migraine in primary care: consultation, prescription, and referral rates in a large population. J Neurol Neurosurg Psychiatry. 2006; 77(3): 385–387.
    CrossRefPubMed
  11. Lantéri-Minet M. The role of general practitioners in migraine management. Cephalalgia. 2008; 28 Suppl 2: 1–8.
    CrossRefPubMed
  12. Becker WJ. The diagnosis and management of chronic migraine in primary care. Headache. 2017; 57(9): 1471–1481.
    CrossRefPubMed
  13. Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016; 128(5): 523–537.
    CrossRefPubMed
  14. Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018; 19(1): 10.
    CrossRefPubMed
  15. Health Data Management database, FarmaProm Polska. . https://www.farmaprom.pl/en/database (01.06.2019).
  16. Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011; 51(7): 1058–1077.
    CrossRefPubMed
  17. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003; 60(3): 441–448.
    CrossRefPubMed
  18. Gültekin M, Balci E, İsmailoğullari S, et al. Awareness of migraine among primary care physicians in Turkey: A regional study. Noro Psikiyatr Ars. 2018; 55(4): 354–357.
    CrossRefPubMed
  19. Bösner S, Hartel S, Diederich J, et al. Diagnosing headache in primary care: a qualitative study of GPs' approaches. Br J Gen Pract. 2014; 64(626): e532–e537.
    CrossRefPubMed
  20. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629–808.
    CrossRefPubMed
  21. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008; 48(8): 1157–1168.
    CrossRefPubMed
  22. May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016; 12(8): 455–464.
    CrossRefPubMed
  23. Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71(8): 559–566.
    CrossRefPubMed
  24. Aguirrezabal I, Pérez de San Román MS, Cobos-Campos R, et al. Effectiveness of a primary care-based group educational intervention in the management of patients with migraine: a randomized controlled trial. Prim Health Care Res Dev. 2019; 20: e155.
    CrossRefPubMed
  25. Becker WJ. Acute migraine treatment in adults. Headache. 2015; 55(6): 778–793.
    CrossRefPubMed
  26. Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013; 53(3): 427–436.
    CrossRefPubMed
  27. Dodick D. Migraine. The Lancet. 2018; 391(10127): 1315–1330.
    CrossRef
  28. Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016; 128(5): 523–537.
    CrossRefPubMed
  29. Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78(17): 1337–1345.
    CrossRefPubMed
  30. Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019; 20(1): 6.
    CrossRefPubMed
  31. Społeczne znaczenie migreny z perspektywy zdrowia publicznego i systemu ochrony zdrowia. Zakład Analiz Ekonomicznych i Systemowych Narodowy Instytut Zdrowia Publicznego – Państwowy Zakład Higieny. 2019. https://www.pzh.gov.pl/wp-content/uploads/2019/06/RAPORT-MIGRENA-ca%C5%82y.pdf.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl